Holen Sie sich die Stockscreener-App
325.28
1.49%
4.76
Handel nachbörslich:
325.28
Schlusskurs vom Vortag:
$320.52
Offen:
$321.57
24-Stunden-Volumen:
1.27M
Relative Volume:
1.37
Marktkapitalisierung:
$42.41B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$-269.70M
KGV:
-155.64
EPS:
-2.09
Netto-Cashflow:
$-75.39M
1W Leistung:
+4.55%
1M Leistung:
+5.03%
6M Leistung:
+22.04%
1J Leistung:
+38.07%
1-Tages-Spanne:
$320.18
$326.30
1-Wochen-Bereich:
$311.25
$329.87
52-Wochen-Spanne:
$205.87
$333.70
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
What drives Alnylam Pharmaceuticals Inc. stock priceFree Stock Selection - jammulinksnews.com
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com
What analysts say about Alnylam Pharmaceuticals Inc. stockOutperformance with explosive growth - jammulinksnews.com
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - 富途牛牛
Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Is Alnylam Pharmaceuticals Inc. a good long term investmentHigh-profit capital plays - jammulinksnews.com
10 Most Undervalued Healthcare Stocks To Buy According To Analysts - Insider Monkey
Lexicography: Clear And Unequivocal - The National Law Review
Lobbying Update: $390,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Truist Securities initiates Alnylam Pharmaceuticals stock with Buy rating By Investing.com - Investing.com Canada
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment and Market Impact - The Globe and Mail
Alnylam’s ALN-4324: A Promising Step in Obesity Treatment - TipRanks
Alnylam’s HELIOS-A Study: A Promising Update for hATTR Amyloidosis Treatment - TipRanks
Alnylam Pharmaceuticals stock price target raised to $290 by Cantor Fitzgerald - Investing.com Canada
Health Check: How Prudently Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Use Debt? - Yahoo Finance
Alnylam's 2025 Earnings and Strategic Momentum: A Case for Biotech Leadership and Long-Term Value Creation - AInvest
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results - Business Wire
Alnylam’s ConTTRibute Study: A Closer Look at ATTR Amyloidosis Treatment - TipRanks
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts - Benzinga
Amvuttra gains UK approval for heart form of ATTR amyloidosis - The Pharma Letter
JPMorgan raises Alnylam Pharmaceuticals stock price target on Amvuttra forecast - Investing.com Canada
Hemophilia Clinical Trials, Companies, Therapeutic - openPR.com
Alnylam Pharmaceuticals Trading Volume Surges to $289 Million Ranking 356th in Daily Volume - AInvest
Alnylam Pharma (ALNY) Receives a Buy from Citi - The Globe and Mail
Alnylam Pharmaceuticals Trading Volume Drops 41.67% to $199 Million Ranking 472nd - AInvest
Jefferies reiterates Buy rating on Alnylam Pharmaceuticals stock, citing strong Amvuttra sales - Investing.com Canada
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyFree Top Growth Stock Recommendations - beatles.ru
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com
Alnylam Pharmaceuticals (ALNY) Target Price Raised by Citigroup | ALNY Stock News - GuruFocus
Alnylam (ALNY) Receives Price Target Boost from Citi | ALNY Stoc - GuruFocus
Analyst Maintains Buy Rating and Raises PT for ALNY | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals’ SWOT analysis: broad label approval boosts stock outlook - Investing.com
BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT - MSN
Alnylam Beats Acuitas Claim on Patents in Pfizer Shot Suit (1) - Bloomberg Law News
Alnylam's Norton site is 'springboard' for expanding manufacturing capacity - The Business Journals
Alnylam Pharma Beats Inventorship Suit Tied To COVID-19 Jab - Law360
Alnylam Pharmaceuticals stock hits all-time high at 326.12 USD - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $377.00 at Needham & Company LLC - MarketBeat
Needham Raises Price Target for Alnylam Pharmaceuticals (ALNY) to $377 | ALNY Stock News - GuruFocus
When Will Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Become Profitable? - Yahoo Finance
Alnylam Stock Plummets 31.67% with 2.10 Billion Shares Traded Ranking 423rd in Volume Amid Legal Victory - AInvest
Alnylam names Pushkal Garg as EVP, chief research and development officer - Yahoo Finance
Alnylam Pharma Appoints New Chief R&D Officer - TipRanks
Alnylam Announces Promotion of Pushkal Garg to Chief Research an - GuruFocus
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer - MarketScreener
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):